All Publications

Data provided by UCSF Profiles, powered by CTSI at UCSF
  1. Collins RA, DiGennaro C, Beninato T, Gartland RM, Chaves N, Broekhuis JM, Reddy L, Lee J, Deimiller A, Alterio MM, Campbell MJ, Lee YJ, Khilnani TK, Stewart LA, O'Brien MA, Alvarado MVY, Zheng F, McAneny D, Liou R, McManus C, Dream SY, Wang TS, Yen TW, Alhefdhi A, Finnerty BM, Fahey TJ, Graves CE, Laird AM, Nehs MA, Drake FT, Lee JA, McHenry CR, James BC, Pasieka JL, Kuo JH, Lubitz CC. Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19. Surgery. 2023 Jan; 173(1):93-100. View in PubMed
  2. Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection. NPJ Breast Cancer. 2021 May 25; 7(1):59. View in PubMed
  3. Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ. Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence. J Mammary Gland Biol Neoplasia. 2020 12; 25(4):417-432. View in PubMed
  4. Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Galon J, Ziv E, Bedognetti D. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021 02 09; 54(2):367-386.e8. View in PubMed
  5. Yanagisawa M, Malik DG, Loehfelm TW, Fananapazir G, Corwin MT, Campbell MJ. Adrenal Tumors Found During Staging and Surveillance for Colorectal Cancer: Benign Incidentalomas or Metastatic Disease? World J Surg. 2020 07; 44(7):2282-2287. View in PubMed
  6. Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. Breast Cancer Res Treat. 2017 01; 161(1):41-50. View in PubMed
  7. Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017 01; 161(1):17-28. View in PubMed
  8. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114. View in PubMed
  9. Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ. Biology of breast cancer in Nigerian women: a pilot study. Ann Afr Med. 2012 Jul-Sep; 11(3):169-75. View in PubMed
  10. Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol. 2012 Nov; 19(12):3979-86. View in PubMed
  11. Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011 Nov; 130(2):635-44. View in PubMed
  12. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100. View in PubMed
  13. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711. View in PubMed
  14. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44. View in PubMed
  15. Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem. 2008 Feb 01; 103(2):624-35. View in PubMed
  16. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Breast cancer growth prevention by statins. Cancer Res. 2006 Sep 01; 66(17):8707-14. View in PubMed
  17. Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice. Cancer Gene Ther. 2006 Nov; 13(11):1002-10. View in PubMed
  18. Kumar AS, Campbell M, Benz CC, Esserman LJ. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol. 2006 May 01; 24(13):2127; author reply 2127-8. View in PubMed
  19. Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther. 2006 Apr; 5(4):1079-86. View in PubMed
  20. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat. 2005 Nov; 94(1):37-46. View in PubMed
  21. Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ. In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother Res. 2005 Jul; 19(7):649-51. View in PubMed
  22. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat. 2005 May; 91(2):163-71. View in PubMed
  23. Shoemaker M, Cohen I, Campbell M. Reduction of MTT by aqueous herbal extracts in the absence of cells. J Ethnopharmacol. 2004 Aug; 93(2-3):381-4. View in PubMed
  24. Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D. Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res. 2002 Nov-Dec; 22(6C):3843-52. View in PubMed
  25. Campbell MJ, Wollish WS, Lobo M, Esserman LJ. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cell Dev Biol Anim. 2002 Jun; 38(6):326-33. View in PubMed
  26. Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G. Ductal growth is impeded in mammary glands of C-neu transgenic mice. Oncogene. 2000 Dec 07; 19(52):5982-7. View in PubMed
  27. Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM. Biological therapies for breast carcinoma: concepts for improvement in survival. Semin Oncol. 1999 Aug; 26(4 Suppl 12):28-40. View in PubMed
  28. Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother. 1999 Feb; 47(6):337-42. View in PubMed
  29. Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann N Y Acad Sci. 1993 Aug 12; 690:385-7. View in PubMed
  30. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992 Oct 22; 327(17):1209-15. View in PubMed
  31. Kwak LW, Campbell MJ, Levy R. Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction. Cancer Res. 1992 Aug 01; 52(15):4117-20. View in PubMed
  32. Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Levy R, Krensky AM. Interleukin 3 is a growth factor for human follicular B cell lymphoma. J Exp Med. 1992 Feb 01; 175(2):371-6. View in PubMed
  33. Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol. 1992 Feb; 29(2):193-203. View in PubMed
  34. Kwak LW, Campbell MJ, Zelenetz AD, Levy R. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood. 1991 Nov 15; 78(10):2768-72. View in PubMed
  35. Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R. Ig VH gene expression among human follicular lymphomas. Blood. 1991 Sep 15; 78(6):1561-8. View in PubMed
  36. Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S. Follicular lymphoma: a model of lymphoid tumor progression in man. Ann Oncol. 1991 Feb; 2 Suppl 2:115-22. View in PubMed
  37. Kwak LW, Campbell M, Levy R. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Cancer Detect Prev. 1991; 15(4):323-5. View in PubMed
  38. Kwak LW, Campbell MJ, Zelenetz AD, Levy R. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood. 1990 Dec 01; 76(11):2411-7. View in PubMed
  39. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol. 1990 Aug 01; 145(3):1029-36. View in PubMed
  40. Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S, Levy R. Idiotypic variation in a human B lymphoma cell line. J Immunol. 1990 Jan 15; 144(2):752-8. View in PubMed
  41. Levy S, Campbell MJ, Levy R. Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V kappa genes to downstream J kappa segment in a murine B cell line. J Exp Med. 1989 Jul 01; 170(1):1-13. View in PubMed
  42. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. Int Rev Immunol. 1989; 4(4):251-70. View in PubMed
  43. Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol. 1988 Nov 01; 141(9):3227-33. View in PubMed
  44. Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC. Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action. J Immunol. 1988 Oct 15; 141(8):2855-60. View in PubMed
  45. Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. J Immunol. 1988 Jul 01; 141(1):333-9. View in PubMed
  46. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol. 1987 Oct 15; 139(8):2825-33. View in PubMed
  47. Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood. 1987 Jan; 69(1):199-210. View in PubMed
  48. Campbell M, Bieber M, Levy R, Teng NN. Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies. J Immunol. 1986 Apr 15; 136(8):2983-8. View in PubMed
  49. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol. 1986 Feb 01; 136(3):1123-30. View in PubMed